2019 Future of Hyperalgesia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 40 pages | ID: 249BBC39A5FEN
VPAResearch

Abstracts

The global demand for Hyperalgesia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Hyperalgesia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Hyperalgesia pipeline companies from advancing their products into Phase 3 or Phase 4.

Hyperalgesia Report Description-

The 2019 pipeline study on Hyperalgesia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Hyperalgesia pipeline compounds.

The Hyperalgesia pipeline guide presents information on all active drugs currently being developed for Hyperalgesia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Hyperalgesia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Hyperalgesia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Hyperalgesia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Hyperalgesia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Hyperalgesia pipeline report includes-

• An overview of Hyperalgesia disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Hyperalgesia pipeline
• Company wise list of Hyperalgesia pipeline
• Mechanism of Action wise Hyperalgesia pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Hyperalgesia pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Hyperalgesia pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Hyperalgesia pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL HYPERALGESIA PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Hyperalgesia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Hyperalgesia pipeline, H1- 2019
3.5 Mechanism of Action wise Hyperalgesia Pipeline Candidates

4 ABIDE THERAPEUTICS INC HYPERALGESIA PIPELINE DETAILS

4.1 Abide Therapeutics Inc Business Profile
4.2 Abide Therapeutics Inc Hyperalgesia Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 BOEHRINGER INGELHEIM GMBH HYPERALGESIA PIPELINE DETAILS

5.1 Boehringer Ingelheim GmbH Business Profile
5.2 Boehringer Ingelheim GmbH Hyperalgesia Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 CARA THERAPEUTICS INC HYPERALGESIA PIPELINE DETAILS

6.1 Cara Therapeutics Inc Business Profile
6.2 Cara Therapeutics Inc Hyperalgesia Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 CHARLESTON LABORATORIES INC HYPERALGESIA PIPELINE DETAILS

7.1 Charleston Laboratories Inc Business Profile
7.2 Charleston Laboratories Inc Hyperalgesia Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 NOVARTIS AG HYPERALGESIA PIPELINE DETAILS

8.1 Novartis AG Business Profile
8.2 Novartis AG Hyperalgesia Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. LATEST HYPERALGESIA DRUG PIPELINE DEVELOPMENTS, 2019

10. APPENDIX

10.1 About Us
10.2 Sources and Methodology
10.3 Contact Information